IN8bio, Inc.
INAB
$1.80
-$0.11-5.85%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.39M | 1.86M | 2.71M | 2.69M | 2.63M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.03M | 3.97M | 5.20M | 5.66M | 6.22M |
| Operating Income | -5.03M | -3.97M | -5.20M | -5.66M | -6.22M |
| Income Before Tax | -4.94M | -3.85M | -5.09M | -5.55M | -6.16M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.94M | -3.85M | -5.09M | -5.55M | -6.16M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.94M | -3.85M | -5.09M | -5.55M | -6.16M |
| EBIT | -5.03M | -3.97M | -5.20M | -5.66M | -6.22M |
| EBITDA | -4.67M | -3.60M | -4.66M | -5.16M | -5.74M |
| EPS Basic | -0.70 | -0.85 | -1.24 | -1.99 | -2.37 |
| Normalized Basic EPS | -0.43 | -0.53 | -0.77 | -1.25 | -1.48 |
| EPS Diluted | -0.70 | -0.85 | -1.24 | -1.99 | -2.37 |
| Normalized Diluted EPS | -0.43 | -0.53 | -0.77 | -1.25 | -1.48 |
| Average Basic Shares Outstanding | 7.10M | 4.54M | 4.12M | 2.78M | 2.59M |
| Average Diluted Shares Outstanding | 7.10M | 4.54M | 4.12M | 2.78M | 2.59M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |